Skip to main content
  • Register
  • Help
  • Contact us

Ampio Pharmaceuticals Inc (AMPE) US$0.0001

Sell:$1.81 Buy:$1.88 Change: $0.14 (8.19%)
Market closed |  Prices as at close on 7 May 2021 | Switch to live prices |
Sell:$1.81
Buy:$1.88
Change: $0.14 (8.19%)
Market closed |  Prices as at close on 7 May 2021 | Switch to live prices |
Sell:$1.81
Buy:$1.88
Change: $0.14 (8.19%)
Market closed |  Prices as at close on 7 May 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Ampio Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused primarily on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. The Company's two lead product candidates in development are Ampion for osteoarthritis of the knee and Optina for diabetic macular edema. Ampion is a sub 5000 molecular weight fraction of commercial human serum albumin (HSA). Optina is a low-dose formulation of danazol. The Ampio segment consists of its biopharmaceuticals compounds and the clinical trials associated with them. The Company is primarily developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; activating specific phosphatase or depleting available phosphate needed for the inflammation process, and decreasing vascular permeability.

Contact details

Address:
373 Inverness Pkwy Ste 200
ENGLEWOOD
80112-5898
United States
Telephone:
+1 (720) 4376500
Website:
ampiopharma.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
AMPE
ISIN:
US03209T1097
Market cap:
$352.13 million
Shares in issue:
195.69 million
Sector:
Pharmaceuticals
Exchange:
New York Stock Exchange
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Michael Macaluso
    Chairman of the Board, Chief Executive Officer
  • Daniel Stokely
    Chief Financial Officer, Treasurer, Secretary
  • Holli Cherevka
    Chief Operating Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.